No buy transactions available for this period
Regeneron Pharmaceuticals, Inc. filed its 13F report for Q4 2025 on February 06, 2026. The portfolio totaled 33.8 M reflecting a -95.17% change from the prior quarter, spanning 2 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 0 new positions and 2 complete exits.
Items:
Total Value:
| Issuer Name | Class | Value | Shares | Option Type |
|---|
Regeneron Pharmaceuticals submitted their Form 13F-HR for the Q4 2025 period on 02/06/2026. This was the only submission for the quarter.
In the Q4 2025 filing, Regeneron Pharmaceuticals reported a managed portfolio value of 33.8 M, consisting of 2 individual positions.
This page displays the raw filing documents. To see which stocks Regeneron Pharmaceuticals bought or sold during Q4 2025, please visit Regeneron Pharmaceuticals's Portfolio Analysis page.